Trial · NCT00856284
Adverse events696
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 696
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Diarrhoea | Gastrointestinal disorders | Metformin + Alogliptin 12.5 mg | 60 | 873 | |
| other | Diarrhoea | Gastrointestinal disorders | Metformin + Alogliptin 25 mg | 60 | 878 | |
| other | Diarrhoea | Gastrointestinal disorders | Metformin + Glipizide | 63 | 869 | |
| other | Upper respiratory tract infection | Infections and infestations | Metformin + Alogliptin 12.5 mg | 84 | 873 | |
| other | Upper respiratory tract infection | Infections and infestations | Metformin + Alogliptin 25 mg | 90 | 878 | |
| other | Upper respiratory tract infection | Infections and infestations | Metformin + Glipizide | 76 | 869 | |
| other | Nasopharyngitis | Infections and infestations | Metformin + Alogliptin 12.5 mg | 78 | 873 | |
| other | Nasopharyngitis | Infections and infestations | Metformin + Alogliptin 25 mg | 67 | 878 | |
| other | Nasopharyngitis | Infections and infestations | Metformin + Glipizide | 61 | 869 | |
| other | Anaemia | Blood and lymphatic system disorders | Metformin + Alogliptin 12.5 mg | 16 | 873 | |
| other | Anaemia | Blood and lymphatic system disorders | Metformin + Alogliptin 25 mg | 37 | 878 | |
| other | Anaemia | Blood and lymphatic system disorders | Metformin + Glipizide | 32 | 869 | |
| other | Nausea | Gastrointestinal disorders | Metformin + Alogliptin 12.5 mg | 28 | 873 | |
| other | Nausea | Gastrointestinal disorders | Metformin + Alogliptin 25 mg | 32 | 878 | |
| other | Nausea | Gastrointestinal disorders | Metformin + Glipizide | 20 | 869 | |
| other | Fatigue | General disorders | Metformin + Alogliptin 12.5 mg | 20 | 873 | |
| other | Fatigue | General disorders | Metformin + Alogliptin 25 mg | 19 | 878 | |
| other | Fatigue | General disorders | Metformin + Glipizide | 28 | 869 | |
| other | Asthenia | General disorders | Metformin + Alogliptin 12.5 mg | 14 | 873 | |
| other | Asthenia | General disorders | Metformin + Alogliptin 25 mg | 15 | 878 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00856284/events